Geneva, May 28 -- International Clinical Trials Registry received information related to the study (NCT06974825) titled 'A Study of BGM0504 in Chinese Patients With Type 2 Diabetes' on May 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Condition:
Type 2 Diabetes
Intervention:
Drug: BGM0504 Administered SC
Drug: BGM0504 Administered SC
Drug: BGM0504 Administered SC
Drug: Semaglutide Administered SC
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 30, 2023
Target Sample Size: 67
Countries of Recru...